Captor TherapeuticsS.A.
Research and experimental development in natural sciences and engineering
Overview
Captor Therapeutics is a biotech company that utilizes Targeted Protein Degradation (TPD) technology to discover and develop therapies for diseases with unmet medical needs, such as cancer and autoimmune disorders. The company operates from Basel, Switzerland, and Wrocław, Poland, and employs advanced techniques like CRISPR/Cas9 for genome editing and its Optigrade™ platform for drug candidate discovery. Their integrated expertise in protein engineering, structural biology, and molecular modeling enables them to optimize lead compounds effectively.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 59.60
- High
- PLN 60.90
- Low
- PLN 59.60
- Volume
- 9.99K
- Avg. vol.
- 10.94K
- Market cap
- PLN 378.66M
- P/E ratio
- –
- EPS
- -PLN 6.97
- Shares outstanding
- 6.35M
- 52-week
- PLN 59.20 – 69.40
- Dividend yield
- –
- Dividend
- –
- Ex dividend date
- –
- ISIN
- PLCPTRT00014
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 441.38k | USD -3.49m | USD -3.08m |
| Q1 2026 | USD 88.60k | USD -3.04m | USD -3.07m |
| Q4 2025 | USD 11.05k | USD -2.58m | USD -2.52m |
| Q3 2025 | USD 504.77k | USD -2.97m | USD -2.88m |
Results for Q3 2026:Nov 19, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2016-01-01. Active
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Dec 31, 2018 | Commercial Companies Code notice |
Public aid
24 public aid cases recorded, with a total value of $66,481,965.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 29, 2023 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $21,101$21,101 | Wrocławski Park Technologiczny S.A. | |
| Jul 17, 2023 | Aid for research and development projects: industrial research | $10.8M$10,754,102 | Prezes Agencji Badań Medycznych | |
| Jul 17, 2023 | Aid for research and development projects: experimental development | $1.7M$1,669,750 | Prezes Agencji Badań Medycznych |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | A first-in-class mcl-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours | $2.7M$2,651,801 | 1.0.11 - Horizon Europe |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the company is represented by one member of the management board. If the management board is a multi-member management board, the company is represented by two members of the management board acting jointly.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| BioceltixS.A. | $616,315.97 | bioceltix.com | ||
| OrthogetS.A. | $532,980.53 | orthoget.com | ||
| VET Cell Techsp. z o.o. | $483,439.81 | vetcelltech.com | ||
| BiocamS.A. | $327,799.68 | biocam.ai | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Poltisssp. z o.o. | $3,843.72 | poltiss.com | ||
| MolecureS.A. | $10.77 | molecure.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-06-25 | Share capital change (552,870.90 PLN → 635,339.70 PLN) | |
| 2025-04-29 | Share capital change (549,557.10 PLN → 552,870.90 PLN) | |
| 2024-12-30 | Share capital change (467,310.40 PLN → 549,557.10 PLN) | |
| 2024-12-12 | Share capital change (466,284.60 PLN → 467,310.40 PLN) | |
| 2024-06-28 | Share capital change (464,571.20 PLN → 466,284.60 PLN) |
FAQ
Last updated: 2026-06-30